The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002331|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : January 16, 2015
PRIMARY: To assess the tolerability of the combination regimen of clarithromycin plus ethambutol with or without clofazimine in patients with disseminated Mycobacterium avium Complex (dMAC).
SECONDARY: To determine the proportion of patients achieving a sterile blood culture along with the time required to achieve it. To determine the duration of bacteriological response, defined as length of time that blood cultures remain sterile.
|Condition or disease||Intervention/treatment||Phase|
|Mycobacterium Avium-intracellular Infection HIV Infections||Drug: Ethambutol hydrochloride Drug: Clarithromycin Drug: Clofazimine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS|
|Study Start Date :||January 1994|
|Actual Primary Completion Date :||March 1995|
|Actual Study Completion Date :||March 1995|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002331